Compared to idiopathic PD, LRRK2-G2019S carrier patients had an increased risk of cancer in general (RR = 1.26, 95% CI = 1.09–1.46), especially for brain (RR = 2.41, 95% CI = 1.06–5.50), breast (RR = 2.57, 95% CI = 1.19–5.58), colon (RR = 1.83, 95% CI = 1.13–2.99), and hematological cancers (RR = 2.05, 95% CI = 1.07–3.92). Here, LRRK2 is linked to cancer.